Research Article



Prevalence of Metabolic Syndrome and Its Determinants in the Middle-aged and Elderly Population in A Southern Coastal Region, Iran (the PERSIAN Cohort Study): A Cross-sectional Study

Ghazal Zoghi ¹, Azim Nejatizadeh ², Mehdi Shahmoradi ³, Zahra Ghaemmaghami ⁴ and Masoumeh Kheirandish ³, ^{*}

¹Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

²Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

³Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

⁴Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

Corresponding author: Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Email: kheirandishm@yahoo.com

Received 2021 June 13; Revised 2021 October 11; Accepted 2021 October 24.

Abstract

Background: Metabolic syndrome (MetS) criteria consist of different but interconnected cardiovascular risk factors, including dysglycemia, hypertension, abdominal obesity, and dyslipidemia.

Objectives: We aimed to determine the prevalence of MetS, its components, and related factors in the southern coastal area of Iran, Bandare-Kong Non-Communicable Diseases (BKNCD).

Methods: This population-based study was performed on the baseline data from participants of BKNCD, which has recruited participants from Bandare-Kong city, one of the 18 distinct geographical areas included in the Prospective Epidemiological Research Studies in IrAN (PERSIAN). MetS was diagnosed based on the National Cholesterol Education Program (NCEP) criteria and the Iranian-specific cut-off for waist circumference (≥ 95 cm). The socioeconomic status (SES) was estimated by multiple correspondence analysis (MCA) based on participants' different properties.

Results: Of 3,927 participants included in this study, 2,230 (56.8%) were female. Age-standardized prevalence of MetS was 34.5%. The most common MetS component was central obesity (45.1%), followed by decreased high-density lipoprotein (42.6%), elevated fasting plasma glucose (39.9%), elevated triglyceride (37.7%), and increased blood pressure (37.5%). Besides, 84.7% of the subjects displayed at least one component of MetS. Binary logistic regression analysis revealed that women aged 65 - 70 years were at higher risk of having MetS compared to those aged 35 - 39 years (adjusted odds ratio [aOR] = 23.37, 95% CI 7.54 - 20.30, P < 0.001). Also, living in rural areas was a risk for MetS in women (aOR = 1.55, 95% CI 1.18 - 2.03, P = 0.002). Employment and education were protective against MetS in women. Being overweight significantly increased the risk of MetS in both men and women. Obesity was more problematic for men (aOR = 16.66, 95% CI 11.65 - 23.81, P < 0.001) compared to women (aOR = 10.43, 95% CI 7.82 - 13.90, P < 0.001). Marital status, education, smoking status, and SES did not significantly predict MetS in men.

Conclusions: A high prevalence of MetS was observed in this study, emphasizing central obesity, high triglyceride, and low highdensity lipoprotein. This calls on the government authorities to establish screening programs to identify individuals with a lower number of abnormal MetS components to prevent them from developing MetS and the resultant cardiovascular complications.

Keywords: Metabolic Syndrome, Abdominal Obesity, Dysglycemia, PERSIAN Cohort Study

1. Background

Metabolic syndrome (MetS), a collection of interconnected cardiovascular risk factors, is characterized by dysglycemia, hypertension, abdominal obesity, and dyslipidemia (1). Several diagnostic criteria have been used for MetS, including the International Diabetes Federation (IDF) criteria (2), the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria (3), and the revised NCEP-ATP III criteria, also known as the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) criteria (4). The prevalence of MetS can differ based on each set of criteria. The prevalence of MetS was about 34.7% based on NCEP-ATP III criteria, 37.4% based on IDF definition, and 41.6% based on AHA/NHLBI definition in Iran in 2007 (5). In this regard, IDF estimates the global prevalence of MetS as about 25% (6); however, this can vary widely based on age, gender, and

Copyright © 2021, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

ethnicity(7).

The presence of all MetS components increases the risk of cardiovascular morbidity and mortality compared to the presence of a single component (8, 9). Some MetS components are believed to be more important than others in that they can be independent predictors of new-onset of other MetS components. Abdominal obesity, defined by high waist circumference (WC) appears to be one of these components (10-12). Abdominal obesity has a negative effect on blood pressure (BP), triglyceride (TG) levels, fasting plasma glucose (FPG), and high-density lipoprotein (HDL) levels (1, 13). Therefore, in addition to the prevalence of MetS, investigating the prevalence of individual MetS components seems to be crucial.

Several factors are associated with MetS, including female gender, obesity, overweight, older age, urbanization, and low educational level. This contributes to the multifactorial nature of MetS (14, 15).

2. Objectives

As MetS has never been evaluated in this region of Iran and due to the unique characteristics of each population that can affect the frequency of MetS, in the current study, we aimed to determine the prevalence of MetS and its components in the PERSIAN Bandare-Kong Cohort study and evaluate the association of age, gender, place of residence, marital status, employment, education, and body mass index (BMI) on MetS and any individual MetS component.

3. Methods

3.1. Participants

We assessed the baseline data from participants of the Bandare-Kong Non-Communicable Diseases (BKNCD). In fact, BKNCD is within the Prospective Epidemiological Research Studies in IrAN (PERSIAN) Cohort in Bandare Kong, Iran, details of which have previously been described (16). The participants of this cohort study were 4,063 individuals aged 35 - 70 years that had been recruited between November 17, 2016, and November 22, 2018, from Bandare-Kong city, Hormozgan province, southern Iran. After excluding incomplete records and pregnant women, 3,927 individuals were included in the final analysis.

3.2. Study Design

A face-to-face interview was conducted by trained interviewers to collect sociodemographic data. Age, place of residence, education, marital status, and cigarette smoking were recorded. The socioeconomic status (SES) was separately estimated by multiple correspondence analysis (MCA), the counterpart of principal component analysis (PCA) for nominal categorical data. The analysis was constructed for the following variables: access to a freezer, access to a washing machine, a dishwasher, a computer, internet, a motorcycle, access to a vacuum cleaner, color TV type, owning a cell phone, a personal computer or a laptop, and international trips in a lifetime. According to their total asset score, subjects were ranked and then grouped into five quintiles, where the 1st quintile indicates the very low (the poorest) group and the 5th quintile indicates the very high (the richest). We combined the two upper and lower quantiles in this study to include enough participants in each category.

The daily ingested foods by the participants were recorded using the Food Frequency Questionnaire (FFQ), and based on their calorie content, the daily calorie intake was calculated. Moreover, by using the metabolic equivalent of tasks (METs), overall daily and weekly energy expenditure of each participant was determined.

Weight was measured using a standard digital scale (to the nearest 0.5 kg) while subjects were shoeless and had minimum clothing. Height was measured while subjects' shoulders were set normally and as they were standing shoeless. After several natural breaths, a stretch-resistant tape was used to measure the midpoint circumference between the inferior margin of the last palpable rib and the top of the iliac crest. The results were recorded as waist circumference (WC). The average of two WC measurements was recorded for each participant.

The largest circumference of the buttocks was recorded as hip circumference (HC). The same stretchresistance tape was used for all the measurements, and the results were recorded to the nearest 0.5 cm. During the measurement, participants were standing with their arms relaxed at the side, as well as evenly distributed body weight and evenly spread feet. By dividing WC by HC, waist-to-hip ratio (WHR) was calculated to the nearest 0.01.

Body mass index was calculated by dividing weight (kg) by the square of height (m). According to the World Health Organization (WHO) guidelines, BMI ≥ 30 was regarded as obese, $25 \leq BMI < 30$ as overweight, $18.5 \leq BMI < 25$ as normal, and BMI < 18.5 kg/m^2 as underweight (17).

A standard mercury sphygmomanometer was used to measure blood pressure (BP) following five minutes of rest. The sphygmomanometer used had an appropriate cuff size. During BP measurement participants were in the seated position, arm supported at heart level, and feet on the floor (6). Two measurements were done at least five min apart, and their average was used for analysis.

Fasting plasma glucose was measured in venous blood samples collected after eight hours of fasting using the glucose oxidase method. Total cholesterol (TC), TG, lowdensity lipoprotien (LDL), and HDL were measured in a separate venous blood sample collected after 12 hours of fasting.

The cut-off value of WC ≥ 95 cm was used for both Iranian men and women based on the study by Azizi et al. (18). The Iranian National Committee of Obesity considered this cut-off as well as the following criteria for MetS, with any three out of five components qualifying a person for MetS (19):

(1) WC \geq 95 cm

(2) FPG \geq 100 mg/dL or drug treatment for elevated blood glucose

(3) HDL < 40 mg/dL in men, < 50 mg/dL in women, or drug treatment for low HDL

(4) TG \geq 150 mg/dL or drug treatment for elevated TG

(5) BP $\geq 130/85\,mmHg$ or drug treatment for hypertension

The study received ethics approval (ethics code: IR.HUMS.REC.1397.176) from the Ethics Committee of Hormozgan University of Medical Sciences, and it complies with the statements of the Declaration of Helsinki. Informed consent was obtained from all subjects and a parent and/or legal guardian for vulnerable population.

3.3. Data Analysis

We used the Statistical Package for the Social Sciences (SPSS) software (version 25.0, Armonk, NY: IBM Corp.) for data analysis. Qualitative variables were described using frequencies and percentages, while quantitative variables were described using means and standard deviations. The binary logistic regression model was used to determine the correlation of MetS with the associated factors. All the potential factors with P-values \leq 0.2 in univariate correlations were simultaneously included in the multivariate logistic regression model using the "enter" method. The area under the receiver operating characteristic (ROC) curve was calculated to determine the prediction performance of the logistic regression model. P-values ≤ 0.05 were considered statistically significant. Of note, we used the direct standardization method to report the age-standardized prevalence of MetS.

4. Results

Of the 3,927 participants in this study, 2,230 (56.8%) were female. Age-standardized prevalence (ASP) of MetS was 26.3 (Iranian-specific criteria) to 35.4% (IDF criteria) in the study population based on different criteria for the diagnosis of MetS. Higher prevalence of MetS was observed in women (31.2-45.6%) compared to men (19.7-30.1%) (Table 1).

Mean age was significantly higher in women with MetS compared to men with MetS (P < 0.001). On the contrary,

mean education years, weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), TG, daily calorie intake, and physical activity were significantly higher in men with MetS compared to their female counterparts. Mean WC, HC, WHR, BMI, LDL, TC, and number of MetS components were significantly higher in women with MetS compared to men with MetS. Mean FPG was significantly higher in women with MetS compared to men with MetS. In general, mean age, weight, HC, WHR, BMI, and TC were significantly higher in those with MetS compared to those without MetS. Contrarily, mean education years, LDL, daily calorie intake, and physical activity were significantly higher in those without MetS. The highest prevalence of MetS was observed in those aged more than 55 - 59 years, living in urban areas, the married, with \leq 6 years of education, the employed, non-smokers, the overweight, those with high SES, and those with low physical activity (Table 2).

The most common component of MetS in this population was central obesity (45.1%), followed by decreased HDL (42.6%), elevated FPG (39.9%), elevated TG (37.7%), and elevated BP(37.5%). The prevalence of MetS components based on different sociodemographic characteristics is summarized in Table 3.

The most prevalent component in women with MetS was central obesity (53.6%), followed by decreased HDL (50.9%) and dysglycemia (40.3%), while hypertriglyceridemia (42.3%) and raised BP (37.7%) were the most common components in their male counterparts (Figure 1). According to the age- and gender-categorized analysis, reduced HDL, abdominal obesity, and elevated TG were the more common elements in younger females, while hypertriglyceridemia, raised WC, and reduced HDL were common in younger men. Meanwhile, high BP and dysglycemia were more common in the elderly population compared to younger adults in both genders. In addition, a significant increase was observed in high BP and dysglycemia from 35 to 70 years of age in both genders (Appendices 1 and 2 in Supplementary File).

Table 4 shows the number of MetS components based on different characteristics of the study population. Among the participants, 15.3% had no components of MetS, 23.7% had only one component, 24.5% had two components, 20.3% had three, 12.2% had four, and 4.1% had all of the MetS components. Besides, 84.7% of the subjects displayed at least one component of MetS. Females, the widowed/divorced, the illiterate, rural residents, the unemployed, and non-smokers showed a higher number of MetS components compared to their counterparts (Appendix 3 in Supplementary File).

Binary logistic regression revealed that the odds of MetS significantly increased with age in women; those aged 65 - 70 years were almost 12.5 folds at higher risk of

Fable 1. Crude and Age-Standardized Prevalence of MetS Based on Different Criteria								
Criteria	Total Poj	pulation	Men	Women				
	Crude	ASP	ASP	ASP				
NCEP	36.9 (35.4 - 38.4)	34.7 (33.3 - 36.1)	24.1 (22.1 - 26.1)	42.6 (40.6 - 44.5)				
IDF	37.3 (35.8 - 38.8)	35.4 (33.9 - 36.8)	21.8 (19.9 - 23.8)	45.6 (43.6 - 47.5)				
Iranian-specific criteria (NCEP)	36.6 (35.1 - 38.1)	34.5 (33.1 - 35.9)	30.1 (27.9 - 32.3)	37.6 (35.8 - 39.5)				
Iranian-specific criteria (IDF)	27.6 (26.2 - 29.0)	26.3 (24.9 - 27.7)	19.7 (17.8 - 21.6)	31.2 (29.3 - 33.0)				

Abbreviations: MetS, metabolic syndrome; ASP, age-standardized prevalence; NCEP, National Cholesterol Education Program; IDF, International Diabetes Federation.



Figure 1. Frequency of MetS components by gender. BP, blood pressure; FPG, fasting plasma glucose; HDL, high-density lipoprotein; TG, triglyceride; WC, waist circumference.

having MetS compared to those aged 35-39 years (OR=12.37, 95% CI 7.54 - 20.30, P < 0.001). Yet, this was not the case for men; although the odds of MetS increased from 50 to 64 years of age, there was a slight decrease in the 65 - 70 years age group. In addition, living in rural areas was a risk for MetS in women (OR = 1.55, 95% CI 1.18 - 2.03, P = 0.002), while the place of residence had no role in the presence of MetS in men. Being employed and educated were protective against MetS in women (OR = 0.72, 95% CI 0.53 - 0.98) and (OR = 0.96, CI: 0.936 - 0.993), then again it did not influence the presence of MetS in men. Being overweight and obese significantly increased the risk of MetS in both men and women. Obesity was more problematic for men (OR = 16.66, 95% CI 11.65 - 23.81, P < 0.001) compared to women (OR = 10.43, 95% CI 7.82 - 13.90, P < 0.001). Marital status, education, smoking status, and SES did not significantly predict the presence of MetS (Table 4).

The area under the ROC curve of the logistic regres-

sion model for prediction of MetS was 0.785 (95% CI: 0.771 - 0.800), which showed the acceptable performance of this model.

5. Discussion

This study demonstrates the first prevalence estimation of MetS amid general population in a southern coastal area of Iran. Our study showed an age-standardized prevalence of 26.3 - 35.4% for MetS based on different criteria in a population aged 35 - 70 years. The IDF criterion for abdominal obesity emphasizes population-specific WC; however, according to the report of the Iranian National Committee of Obesity (19), the harmonized definition of MetS using identical cut-offs of WC for both genders and requiring any three components with no obligatory component for the diagnosis of MetS appears to be more appropriate for

Uncorrected Proof

Zoghi G et al.

Table 2. Sociodemogr	aphic and Anthro	pometric Feature	s of Participan	ts Based on the Pro	esence of MetS Acc	cording to Iran	ian-specific Defin	ition (N = 3,927) ^a	
Variables	No MetS		P-Value*	MetS		P.Value*	Total		P-Value*
variabics	Men	women	1-value	Men	Women	1-value	No MetS	MetS	1-value
Age (y)	47.18 ± 9.19	45.79 ± 8.66	< 0.001	50.87 ± 9.89	51.91 ± 8.92	< 0.001	46.44 ± 8.93	51.52 ± 9.31	< 0.001
Weight (kg)	71.38 ± 13.10	64.96 ± 13.19	< 0.001	82.26 ± 13.93	73.24 ± 13.08	< 0.001	67.96 ± 13.53	76.59 ± 14.09	< 0.001
WC(cm)	87.30 ± 10.43	92.20 ± 11.29	< 0.001	97.23 ± 9.30	102.41 ± 9.77	< 0.001	89.92 ± 11.17	100.49 ± 9.92	< 0.001
HC(cm)	95.99 ± 7.64	100.25 ± 9.87	< 0.001	101.56 ± 8.09	104.53 ± 10.30	< 0.001	98.26 ± 9.15	103.42 ± 9.65	< 0.001
WHR	0.91 ± 0.06	0.92 ± 0.07	< 0.001	0.96 ± 0.48	0.98 ± 0.06	< 0.001	0.91 ± 0.06	0.97 ± 0.06	< 0.001
SBP (mmHg)	116.97 ± 14.25	111.28 ± 14.55	< 0.001	128.23 ± 18.31	126.24 ± 19.01	< 0.001	113.93 ± 14.69	126.98 ± 18.77	< 0.001
DBP (mmHg)	76.44 ± 9.31	73.00 ± 9.72	< 0.001	82.62 ± 9.96	80.12 ± 10.31	< 0.001	74.61 ± 9.68	81.05 ± 10.25	< 0.001
FPG (mg/dL)	98.60 ± 29.84	95.40 ± 30.04	< 0.001	121.21 ± 47.90	131.67 ± 57.00	< 0.001	96.89 ± 29.98	127.78 ± 54.01	< 0.001
TC (mg/dL)	198.71 ± 37.70	202.57 ± 40.88	0.014	199.66 ± 50.89	207.90 ± 44.30	0.004	200.77 ± 39.47	204.83 ± 47.01	0.006
TG (mg/dL)	124.13 ± 67.86	101.45 ± 42.94	< 0.001	203.17 ± 149.11	165.14 ± 80.78	< 0.001	112.04 ± 57.09	179.28 ± 112.67	< 0.001
HDL (mg/dL)	46.38 ± 8.96	52.62 ± 10.81	< 0.001	40.38 ± 9.64	47.09 ± 10.03	< 0.001	49.71 ± 10.46	44.59 ± 10.40	< 0.001
LDL (mg/dL)	127.84 ± 32.44	129.65 ± 34.06	0.177	120.18 ± 34.20	128.40 ± 37.55	0.425	128.81 ± 33.32	125.34 ± 36.54	0.003
Physical activity (METS)	293.05 + 58.39	279.68 + 31.17	< 0.001	275.32 + 42.09	272.30 + 32.27	< 0.001	285.92 ± 46.41	273.42 + 36.25	< 0.001
Number of MetS components	1.12 ± 0.80	1.17 ± 0.76	0.151	3.43 ± 0.62	3.63 ± 0.71	< 0.001	1.15 ± 0.78	3.56 ± 0.69	< 0.001
Age groups (v)			0.006			< 0.001			< 0.001
Age groups (y)	202 (26.0)	405 (20.5)	0.000	02 (17.4)	04(10.4)	< 0.001	708 (28.4)	187 (12.0)	< 0.001
33-39	302 (20.0)	400 (30.0)		93 (17.4)	94 (10.4)		708 (28.4)	187 (15:0)	
40-44	232(19.9)	291(21.9)		82 (15.4)	120 (13.3)		523 (21.0)	202 (14.1)	
45-49	214 (18.4)	239 (18.0)		70 (13.1)	146 (16.2)		453 (18.2)	216 (15.0)	
50-54	140 (12.0)	160 (12.0)		73 (13.7)	167 (18.5)		300 (12.0)	240 (16.7)	
55-59	125 (10.7)	111 (8.4)		82 (15.4)	182 (20.2)		236 (9.5)	264 (18.4)	
60-64	94 (8.1)	71 (5.3)		87 (16.3)	108 (12.0)		165 (6.6)	195 (13.6)	
65 - 70	56 (4.8)	50 (3.8)		47 (8.8)	85 (9.4)		106 (4.3)	132 (9.2)	
Place of residence			0.526			< 0.001			0.026
Urban	996 (46.4)	1149 (53.6)		469 (39.1)	730 (60.9)		2145 (64.1)	1199 (35.9)	
Rural	167 (48.3)	179 (51.7)		65 (27.4)	172 (72.6)		346 (59.3)	237 (40.7)	
Marital status			< 0.001			0.022			0.001
Single	16 (23.9)	51 (76.1)		5 (19.2)	21 (80.8)		67 (72.0)	226 (28.0)	
Married	1135 (50.5)	1113 (49.5)		524 (41.4)	742 (58.6)		2248 (64.0)	1266 (36.0)	
Wid- owed/Divorced	12 (6.8)	164 (93.2)		5 (3.5)	139 (96.5)		176 (55.0)	144 (45.0)	
Education			< 0.001			< 0.001			< 0.001
< 6 years	498 (36.5)	868 (63.5)		254 (25.7)	733 (74.3)		1366 (58.1)	987 (41.9)	
6 - 12 years	529 (59.6)	358 (40.4)		213 (58.7)	150 (41.3)		887(71.0)	363 (29.0)	
> 12 years	136 (57.1)	102 (42.9)		67(77.9)	19 (22.1)		238 (73.5)	86 (26.5)	
Occupation			< 0.001			< 0.001			< 0.001
Employed	1000 (80.0)	250 (20.0)		419 (82.0)	92 (18.0)		1250 (71.0)	511 (29.0)	
Unemployed	163 (13.1)	1078 (86.9)		115 (12.4)	810 (87.6)		1241 (57.3)	925 (42.7)	
BMI categories			< 0.001			< 0.001			< 0.001
Underweight	57 (56.4)	44 (43.6)		3 (50.0)	3 (50.0)		101 (94.4)	6 (5.6)	
Normal	599 (53.5)	520 (46.5)		100 (47.4)	111 (52.6)		1119 (84.1)	211 (15.9)	
Overweight	408 (45.8)	482 (54.2)		258 (39.8)	390 (60.2)		890 (57.9)	648 (42.1)	
Obese	99 (26.0)	282 (74.0)		173 (30.3)	398 (69.7)		381(40.0)	571 (60.0)	
Smoking	383 (99.2)	3(0.8)	< 0.001	186 (97.4)	5 (2.6)	0.282	386 (66.9)	191 (33.1)	0.061
SES			< 0.001			0.788			0.981
Very low	173 (36.7)	298 (63.3)		59 (21.1)	220 (78.9)		471 (62.8)	279 (37.2)	
Low	207 (43.3)	271 (56.7)		88 (31.7)	190 (68.3)		478 (63.2)	278 (36.8)	
Average	251(48.0)	272 (52.0)		118 (40.3)	175 (59.7)		523 (64.1)	293 (35.9)	
High	266 (49.7)	269 (50.3)		135 (43.1)	178 (56.9)		535 (63.1)	313 (36.9)	
Very high	266 (55.0)	218 (45.0)		134 (49.1)	139 (50.9)		484 (63.9)	273 (36.1)	
Low physical activity	1159 (46.6)	1328 (53.4)	0.047	534 (37.2)	902(62.8)		2487(63.4)	1436 (36.6)	0.304

Abbreviations: SD, standard deviation; MetS, metabolic syndrome; WC, waist circumference; HC, hip circumference; WHR, waist to hip ratio; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; METS, metabolic equivalent of tasks; SES, socioeconomic status.

Uncorrected Proof

Zoghi G et al.

VariablesCentral ObesityElevated FFGElevated TGDecreased HDLElevated FPAge (y)35 - 39350 (39.1)202 (22.6)248 (27.7)383 (42.8)147 (16.4)40 - 44319 (44.0)222 (30.6)224 (32.3)340 (46.9)149 (20.6)45 - 49301 (45.0)249 (37.2)226 (33.8)305 (45.6)224 (33.5)50 - 54257 (49.4)270 (50.0)237 (43.9)218 (40.4)251 (46.5)55 - 59256 (51.2)286 (57.2)247 (49.4)191 (32.2)200 (53.0)66 - 64166 (46.1)200 (55.6)171 (47.5)141 (39.2)230 (63.9)65 - 70111 (46.6)136 (57.1)119 (50.0)96 (40.3)181 (76.1)Pvalue< 0.001< 0.001< 0.0010.019< 0.001Gender </th <th>able 3. Prevalence of MetS Components b</th> <th>by Sociodemographic Characte</th> <th>eristics According to Irani</th> <th>an-specific Definition An</th> <th>nong Population (N = 3,927)</th> <th>a</th>	able 3. Prevalence of MetS Components b	by Sociodemographic Characte	eristics According to Irani	an-specific Definition An	nong Population (N = 3,927)	a
Age (y)33 - 39350 (39.1)202 (22.6)248 (27.7)383 (42.8)147 (16.4)40 - 44319 (44.0)222 (30.6)234 (22.3)340 (46.9)149 (20.6)45 - 49301 (45.0)249 (37.2)226 (31.8)305 (45.6)224 (33.5)50 - 54267 (49.4)270 (50.0)277 (43.9)218 (40.4)251 (45.5)55 - 59256 (51.2)286 (57.2)247 (49.4)191 (38.2)290 (58.0)60 - 64166 (46.1)200 (55.6)171 (47.5)141 (39.2)230 (63.9)65 - 70111 (46.6)136 (57.1)191 (50.0)96 (40.3)181 (76.1)Pvalue< 0.001< 0.001< 0.0010.019< 0.001Gender </th <th>Variables</th> <th>Central Obesity</th> <th>Elevated FPG</th> <th>Elevated TG</th> <th>Decreased HDL</th> <th>Elevated BP</th>	Variables	Central Obesity	Elevated FPG	Elevated TG	Decreased HDL	Elevated BP
35-39 350 (91.1) 202 (22.6) 248 (27.7) 383 (42.8) 147 (16.4) 40 - 44 319 (44.0) 222 (30.6) 234 (32.3) 340 (45.9) 149 (20.6) 45 - 49 301 (45.0) 249 (37.2) 226 (33.8) 305 (45.6) 224 (33.5) 50 - 54 267 (34.9) 270 (50.0) 237 (43.9) 218 (40.4) 220 (58.0) 66 - 64 166 (46.1) 200 (55.6) 171 (47.5) 141 (39.2) 230 (63.9) 65 - 70 111 (46.6) 156 (57.1) 19 (50.0) 96 (40.3) 181 (76.1) Pvalue <0.001	Age (y)					
40-44319(44.0)222(30.6)234(32.3)340(46.9)149(20.6)45-49301(45.0)249(37.2)226(33.8)305(45.6)224(33.5)50-54267(49.4)270(50.0)271(43.0)218(40.4)210(50.6)55-59256(51.2)286(57.2)247(49.4)191(38.2)220(58.0)60-64166(46.1)200(55.6)171(47.5)141(39.2)230(51.6)65-70111(46.6)136(57.1)119(50.0)96(40.3)181(76.1)Pvalue< 0.001	35 - 39	350 (39.1)	202 (22.6)	248 (27.7)	383 (42.8)	147 (16.4)
45-4930(45.0)249(37.2)226(33.8)305(45.6)224(33.5)50 - 54267(49.4)270(50.0) $327(43.9)$ $18(40.4)$ 251(45.5)55 - 59256 (51.2)286 (57.2) $247(49.4)$ 191(38.2)290 (58.0)60 - 64166 (46.1)200 (55.6)171(47.5)141 (39.2)230 (63.9)65 - 70111 (46.6)136 (57.1)109 (50.0)96 (40.3)181 (76.1)Palue< 0.001	40 - 44	319 (44.0)	222 (30.6)	234 (32.3)	340 (46.9)	149 (20.6)
$50 \cdot 54$ $267(49.4)$ $270(50.0)$ $237(43.9)$ $218(40.4)$ $251(45.5)$ $55 \cdot 59$ $256(51.2)$ $286(57.2)$ $247(49.4)$ $191(38.2)$ $290(58.6)$ $60 \cdot 64$ $166(46.1)$ $200(55.6)$ $171(47.5)$ $141(39.2)$ $220(63.9)$ $65 \cdot 70$ $111(46.6)$ $36(57.1)$ $19(50.0)$ $96(0.0)$ $817(51.0)$ $Pvalue$ < 0.001 < 0.001 < 0.001 0.019 < 0.001 6ender V V V V V $Prade$ $574(33.8)$ $666(392.9)$ $718(42.3)$ $539(31.8)$ $639(37.7)$ $Penale$ $199(53.6)$ $899(40.3)$ $754(43.4)$ $135(50.9)$ $833(37.4)$ $Pvalue$ 0.001 0.098 0.001 < 0.001 < 0.001 $Pvalue$ 0.001 $1254(37.5)$ $1258(37.6)$ $1508(45.1)$ $1189(35.6)$ $Rural$ $284(48.7)$ $311(53.3)$ $224(38.4)$ $166(28.5)$ $233(48.5)$ $Pvalue$ 0.056 0.001 0.722 < 0.001 < 0.001 $Maried$ $157(44.7)$ $138(39.4)$ $135(30.0)$ $1482(42.2)$ $1222(36.8)$ $Pvalue$ 0.008 0.032 0.055 0.081 < 0.001 $Pvalue$ 0.008 0.032 0.055 0.081 < 0.001 $Pvalue$ 0.001 $< 338(48.2)$ $798(45.8)$ $911(41.6)$ $86(50.6)$ $Pvalue$ 0.001 < 0.001 < 0.005 0.143 < 0.001 $Pvalue$ 0.001	45 - 49	301 (45.0)	249 (37.2)	226 (33.8)	305 (45.6)	224 (33.5)
55 - 59 $256 (512)$ $286 (572)$ $247 (49.4)$ $191 (38.2)$ $290 (58.0)$ $60 - 64$ $166 (46.1)$ $200 (55.6)$ $171 (47.5)$ $141 (192.2)$ $230 (63.9)$ $65 - 70$ $III (46.6)$ $156 (57.1)$ $19 (50.0)$ $96 (40.3)$ $181 (76.1)$ $Pvalue$ <0.001 <0.001 <0.001 0.019 <0.010 Gender $<0.001<0.001<0.019<0.010Pvalue<0.0010.498<0.001<0.0010.847Pvalue<0.0010.498<0.001<0.0010.847Pvalue<0.0010.498<0.001<0.0010.847Pvalue<0.0010.498<0.001<0.0010.847Pvalue<0.0010.498<0.001<0.0010.847Pvalue<0.0010.498<0.001<0.0010.847Pvalue<0.0010.498<0.001<0.0010.847Pvalue0.056<0.001<0.001<0.001<0.001<0.001Pvalue0.056<0.0010.72<0.001<0.001<0.001Pvalue0.032224 (38.4)166 (28.5)232 (36.8)37 (39.8)24 (25.8)Pvalue0.0080.0320.0550.081<0.001<0.001Pvalue0.0080.0320.0550.081<0.021<0.01Pvalue50 - 54267 (49.4)270 (50.0)237 (43.9)218 (40.4)251 (46.5)$	50 - 54	267 (49.4)	270 (50.0)	237 (43.9)	218 (40.4)	251 (46.5)
60-64166(46.1)200 (55.6)171 (47.5)141 (39.2)230 (63.9)65-70111 (46.6)136 (57.1)19 (50.0)96 (40.3)181 (76.1)Pvalue< 0.001	55 - 59	256 (51.2)	286 (57.2)	247 (49.4)	191 (38.2)	290 (58.0)
65-70III (46.6)J36 (57.1)II9 (50.0)96 (40.3)181 (76.1)Pvalue< 0.001	60 - 64	166 (46.1)	200 (55.6)	171 (47.5)	141 (39.2)	230 (63.9)
Palue< 0.001< 0.001< 0.0010.019< 0.001GenderMale574 (33.8)666 (39.2)718 (42.3)539 (18.8)639 (37.7)Penale1196 (53.6)899 (40.3)764 (30.4)135 (50.9)833 (37.4)Palue196 (53.6)899 (40.3)764 (30.4)135 (50.9)833 (37.4)Phator1486 (44.4)1254 (37.5)1258 (37.6)1508 (45.1)1189 (35.6)Rural284 (48.7)311 (53.3)224 (38.4)166 (28.5)283 (48.6)Palue0.056< 0.0010.712< 0.001< 0.001Parale33 (35.5)32 (34.4)24 (25.8)37 (39.8)24 (25.8)Single33 (35.5)32 (34.4)24 (25.8)37 (39.8)24 (25.8)Palue0.056< 0.0010.0320.055203 (35.6)156 (48.1)Palue157 (44.7)1385 (39.4)1335 (38.0)1482 (42.2)129 (36.8)Palue166 (51.9)148 (46.3)20.35135 (48.2)156 (48.1)156 (48.8)Palue157 (44.7)138 (38.2)698 (40.2)763 (43.9)886 (51.0)Palue50.01< 0.001< 0.0010.0050.43< 0.001Palue50.01< 0.001< 0.001< 0.0050.43< 0.001Palue618 (51.9)638 (36.2)757 (33.8)618 (51.1)540 (30.1)Palue618 (51.2)638 (36.2)675 (33.3)618 (51.1)540 (30.1)Palue618 (51.2)	65 - 70	111 (46.6)	136 (57.1)	119 (50.0)	96 (40.3)	181 (76.1)
Gender Male 574 (33.8) 666 (39.2) 718 (42.3) 539 (31.8) 639 (37.7) Female 196 (53.6) 899 (40.3) 764 (34.3) 135 (50.9) 833 (37.4) Pvalue < 0.01	P-value	< 0.001	< 0.001	< 0.001	0.019	< 0.001
Male $574(33.8)$ $666(39.2)$ $718(42.3)$ $539(31.8)$ $639(37.7)$ Female $1196(53.6)$ $899(40.3)$ $764(34.3)$ $1135(50.9)$ $833(37.4)$ Pvalue < 0.001 0.498 < 0.001 < 0.001 0.847 Place of residence U U U $I189(53.6)$ $I189(53.6)$ $I189(53.6)$ Rural $284(48.7)$ $311(53.3)$ $224(38.4)$ $I56(84.5)$ $28(48.7)$ Pvalue 0.056 0.001 0.712 < 0.001 < 0.001 Pvalue $33(35.5)$ $32(34.4)$ $24(25.8)$ $37(39.8)$ $24(25.8)$ Single $33(35.5)$ $32(34.4)$ $24(25.8)$ $37(39.8)$ $24(25.8)$ Married $1571(44.7)$ $1385(39.4)$ $1335(38.0)$ $1482(42.2)$ $1292(36.8)$ Pvalue 0.008 0.032 0.055 0.081 < 0.001 Pvalue 0.008 0.032 0.055 0.081 < 0.001 Pvalue 0.008 0.032 0.055 0.081 < 0.001 Pvalue $916(41.8)$ $727(32.2)$ $784(35.8)$ $911(41.6)$ $586(26.8)$ Pvalue $916(41.8)$ $727(32.2)$ $784(35.8)$ $911(41.6)$ $586(26.8)$ Pvalue $618(35.1)$ $618(35.1)$ $540(30.7)$ $540(30.7)$ $540(30.7)$ Pvalue $618(35.1)$ $618(35.1)$ $540(30.7)$ $92(43.0)$ $92(43.0)$ Pvalue $618(35.1)$ $618(35.2)$ $675(38.3)$ $618(35.1)$ $540(30.7)$ Pv	Gender					
Female 1196 (53.6) 899 (40.3) 764 (34.3) 1135 (50.9) 833 (37.4) Pvalue < 0.001	Male	574 (33.8)	666 (39.2)	718 (42.3)	539 (31.8)	639 (37.7)
Pvalue < 0.001 0.498 < 0.001 < 0.001 0.847 Place of residenceUrban $1486 (44.4)$ $1254 (37.5)$ $1258 (37.6)$ $508 (45.1)$ $1189 (35.6)$ Rural $284 (48.7)$ $311 (53.3)$ $224 (38.4)$ $166 (28.5)$ $283 (48.5)$ Pvalue 0.056 < 0.001 0.712 < 0.001 < 0.001 Marital statusSingle $33 (35.5)$ $32 (34.4)$ $24 (25.8)$ $37 (39.8)$ $24 (25.8)$ Married $1571 (44.7)$ $1385 (39.4)$ $1335 (38.0)$ $1482 (42.2)$ $1292 (36.8)$ Widowed/divored $166 (51.9)$ $148 (46.3)$ $123 (38.4)$ $155 (48.4)$ $156 (48.8)$ Pvalue 0.008 0.032 0.055 0.01 < 0.01 Iliterate $854 (49.2)$ $838 (48.2)$ $698 (40.2)$ $753 (43.9)$ $886 (51.6)$ Iliterate 0.001 < 0.01 < 0.01 < 0.001 < 0.001 < 0.001 Occupation < 0.001 < 0.001 < 0.490 < 0.001 < 0.001 Pvalue < 0.001 < 0.001 < 0.490 < 0.001 < 0.001	Female	1196 (53.6)	899 (40.3)	764 (34.3)	1135 (50.9)	833 (37.4)
Place of residence Urban 1486 (44.4) 1254 (37.5) 1258 (37.6) 1508 (45.1) 1189 (35.6) Rural 284 (48.7) 311 (53.3) 224 (38.4) 166 (28.5) 283 (48.5) P-value 0.056 < 0.001	P-value	< 0.001	0.498	< 0.001	< 0.001	0.847
Urban 1486 (44.4) 1254 (37.5) 1258 (37.6) 1508 (45.1) 1189 (35.6) Rural 284 (48.7) 311 (53.3) 224 (38.4) 166 (28.5) 283 (48.5) Pvalue 0.056 < 0.001	Place of residence					
Rural 284 (48.7) 311 (53.3) 224 (38.4) 166 (28.5) 283 (48.5) P-value 0.056 < 0.001	Urban	1486 (44.4)	1254 (37.5)	1258 (37.6)	1508 (45.1)	1189 (35.6)
Pvalue 0.056 < 0.001 0.712 < 0.001 < 0.001 Marital status	Rural	284 (48.7)	311 (53.3)	224 (38.4)	166 (28.5)	283 (48.5)
Marital status Single 33 (35.5) 32 (34.4) 24 (25.8) 37 (39.8) 24 (25.8) Married 1571 (44.7) 1385 (39.4) 1335 (38.0) 1482 (42.2) 1292 (36.8) Widowed/divorced 166 (51.9) 148 (46.3) 123 (38.4) 155 (48.4) 156 (48.8) Pvalue 0.008 0.032 0.055 0.081 < 0.001	P-value	0.056	< 0.001	0.712	< 0.001	< 0.001
Married 33 (35.5) 32 (34.4) 24 (25.8) 37 (35.5) 24 (25.8) Married 1571 (44.7) 1385 (39.4) 1335 (38.0) 1482 (42.2) 1292 (36.8) Widowed/divorced 166(51.9) 148 (46.3) 123 (38.4) 155 (48.4) 156 (48.8) Pvalue 0.008 0.032 0.055 0.081 < 0.001	Marital status	22 (25 5)	22 (24.4)	24 (25.8)	27 (20.8)	24 (25.8)
Matried 15/1 (44.7) 1385 (33.4) 1335 (38.0) 1482 (42.2) 1292 (36.8) Widowed/divorced 166(51.9) 148 (46.3) 123(38.4) 155 (48.4) 156 (48.8) P-value 0.008 0.032 0.055 0.081 < 0.001	Manniad	33 (35.5)	32 (34.4)	24 (25.8)	37 (39.8)	24 (25.8)
Witdowedulvorced 166(51.9) 148 (46.3) 123(38.4) 155 (48.4) 156 (48.8) Pvalue 0.008 0.032 0.055 0.081 < 0.001	Married	15/1(44./)	1385 (39.4)	1335 (38.0)	1482 (42.2)	1292 (36.8)
Pvalue 0.008 0.032 0.055 0.081 < 0.001 Education Education S54 (49.2) 838 (48.2) 698 (40.2) 763 (43.9) 886 (51.0) Literate 916 (41.8) 727 (33.2) 784 (35.8) 911 (41.6) 586 (26.8) P-value < 0.001	widowed/divorced	166(51.9)	148 (46.3)	123(38.4)	155 (48.4)	156(48.8)
Function 854 (49.2) 838 (48.2) 698 (40.2) 763 (43.9) 886 (51.0) Literate 916 (41.8) 727 (33.2) 784 (35.8) 911 (41.6) 586 (26.8) P-value < 0.001	P-value	0.008	0.032	0.055	0.081	< 0.001
Initiate BST (BL)	Illiterate	854 (49.2)	838 (48.2)	698 (40.2)	763 (43 9)	886(510)
Include 5x0 (m/y) 7x1 (552) 7x1 (552) 7x1 (165) 5x0 (200) P-value < 0.001	Literate	916 (41.8)	727 (33.2)	784 (35.8)	911 (41.6)	586 (26.8)
Number of the construction <th< td=""><td>P-value</td><td>< 0.001</td><td>< 0.001</td><td>0.005</td><td>0.143</td><td>< 0.001</td></th<>	P-value	< 0.001	< 0.001	0.005	0.143	< 0.001
Employed 618 (35.1) 638 (36.2) 675 (38.3) 618 (35.1) 540 (30.7) Unemployed 1152 (53.2) 927 (42.8) 807 (37.3) 1056 (18.8) 932 (43.0) P-value < 0.001	Occupation	< 0.001	< 0.001	0.005	0.145	0.001
Unemployed 1152 (53.2) 927 (42.8) 807 (37.3) 1056 (18.8) 932 (43.0) P-value < 0.001	Employed	618 (35.1)	638 (36.2)	675 (38.3)	618 (35.1)	540 (30.7)
P-value < 0.001 < 0.001 0.490 < 0.001 < 0.001	Unemployed	1152 (53.2)	927 (42.8)	807 (37.3)	1056 (18.8)	932 (43.0)
	P-value	< 0.001	< 0.001	0.490	< 0.001	< 0.001
BMI	BMI					
Underweight 0 (0.0) 12 (11.2) 15 (14.0) 27 (25.2) 13 (12.1)	Underweight	0 (0.0)	12 (11.2)	15 (14.0)	27 (25.2)	13 (12.1)
Normal 67(5.0) 442(33.2) 367(27.6) 459(34.5) 396(29.8)	Normal	67 (5.0)	442 (33.2)	367 (27.6)	459 (34.5)	396 (29.8)
Overweight 796 (51.8) 658 (42.8) 661 (43.0) 722 (46.9) 627 (40.8)	Overweight	796 (51.8)	658 (42.8)	661(43.0)	722 (46.9)	627 (40.8)
Obese 907(95.3) 453(47.6) 439(46.1) 466(48.9) 436(45.8)	Obese	907 (95.3)	453 (47.6)	439 (46.1)	466 (48.9)	436 (45.8)
P-value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001	P-value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
Smoking	Smoking					
Yes 184 (31.9) 216 (37.4) 250 (43.3) 207 (35.9) 226 (39.2)	Yes	184 (31.9)	216 (37.4)	250 (43.3)	207 (35.9)	226 (39.2)
No 1586 (47.3) 1349 (40.3) 1232 (36.8) 1467 (43.8) 1246 (37.2)	No	1586 (47.3)	1349 (40.3)	1232 (36.8)	1467 (43.8)	1246 (37.2)
P-value < 0.001 0.199 0.003 < 0.001 0.366	P-value	< 0.001	0.199	0.003	< 0.001	0.366
SES	SES					
Very low 332 (44.3) 295 (39.3) 260 (34.7) 358 (47.7) 292 (38.9)	Very low	332 (44.3)	295 (39.3)	260 (34.7)	358 (47.7)	292 (38.9)
Low 335 (44.3) 294 (38.9) 288 (38.1) 336 (44.4) 283 (37.4)	Low	335 (44.3)	294 (38.9)	288 (38.1)	336 (44.4)	283 (37.4)
Average 358 (43.9) 316 (38.7) 298 (36.5) 363 (44.5) 298 (36.5)	Average	358 (43.9)	316 (38.7)	298 (36.5)	363 (44.5)	298 (36.5)
High 401(47.3) 352 (41.5) 327 (38.6) 337 (39.7) 323 (38.1)	High	401 (47.3)	352 (41.5)	327 (38.6)	337 (39.7)	323 (38.1)
Very high 344 (45.4) 308 (40.7) 309 (40.8) 280 (37.0) 276 (36.5)	Very high	344 (45.4)	308 (40.7)	309 (40.8)	280 (37.0)	276 (36.5)
P-value 0.632 0.736 0.143 < 0.001 0.832	P-value	0.632	0.736	0.143	< 0.001	0.832
Mets	MetS	1004 ((12)	1053 ((53)	10(1(4))	017 (5 4 5)	000((775)
$\frac{105}{1054(01.2)} = \frac{1053(07.3)}{1051(41.6)} = \frac{1077(47.3)}{917(54.8)} = \frac{1077(47.3)}{993(67.5)}$	ies	1084 (61.2)	1053 (67.3)	1001 (41.6)	917 (54.8)	993 (67.5)
INU DSD (38.8) 512 (32.7) 421 (28.4) 757 (45.2) 479 (32.5) Durling COOL	NU	(38.8)	512 (32.7)	421(28.4)	/5/(45.2)	4/9 (32.5)
Total 1770 (45.1) 1565 (39.9) 1482 (37.7) 1674 (42.6) 1472 (37.5)	Total	1770 (45.1)	1565 (39.9)	1482 (37.7)	1674 (42.6)	1472 (37.5)

^aValues are expressed as No. (%) unless otherwise indicated.

Shiraz E-Med J. In Press(In Press):e116838.

Zoghi G et al.

Variables		Men						Women		
variables	В	S.E.	P-Value	OR	95% CI	В	S.E.	P-Value	OR	95% CI
Age (y)										
35 - 39 ^a										
40 - 44	0.234	0.194	0.229	1.26	0.86 - 1.85	0.556	0.171	0.001	1.74	1.25 - 2.44
45-49	0.307	0.206	0.135	1.36	0.91-2.04	0.881	0.174	< 0.001	2.41	1.72 - 3.39
50-54	0.839	0.219	< 0.001	2.31	1.51 - 3.56	1.568	0.182	< 0.001	4.80	3.36 - 6.85
55 - 59	1.233	0.230	< 0.001	3.43	2.19 - 5.38	2.110	0.194	< 0.001	8.25	5.64 - 12.07
60 - 64	1.614	0.244	< 0.001	5.02	3.12 - 810	2.234	0.226	< 0.001	9.34	6.00 - 14.54
65 - 70	1.56	0.296	< 0.001	4.75	2.66 - 8.49	2.516	0.253	< 0.001	12.37	7.54 - 20.30
Education years	-0.004	0.014	0.783	0.996	0.969 - 1.024	-0.037	0.015	0.014	0.964	0.936 - 0.993
Place of residence										
Urban ^a										
Rural	0.042	0.179	0.814	1.04	0.73 - 1.48	0.435	0.138	0.002	1.55	1.18 - 2.03
Marital status										
Single ^a										
Married	-0.163	0.596	0.784	0.85	0.26 - 2.73	-0.451	0.320	0.159	0.64	0.34 - 1.19
Wid- owed/divorced	-0.566	0.847	0.504	0.57	0.11 - 2.99	-0.0653	0.349	0.061	0.52	0.26 - 1.03
Occupation										
Unemployed ^a										
Employed	-0.023	0.174	0.897	0.98	070 - 1.37	-0.323	0.156	0.038	0.72	0.53 - 0.98
BMI										
Underweight and normal ^a										
Overweight	1.57	0.142	< 0.001	4.80	3.63 - 6.34	1.659	0.138	< 0.001	5.26	4.01-6.89
Obese	2.813	0.182	< 0.001	16.66	11.65 - 23.81	2.344	0.147	< 0.001	10.43	7.82 - 13.90
Smoking status										
No ^a										
Yes	-0.076	0.130	0.558	0.93	0.72 - 1.20	-1.173	0.769	0.127	0.31	0.07-1.40
SES										
Very low ^a										
Low	0.157	0.224	0.485	1.17	0.75 - 1.82	-0.065	0.151	0.665	0.94	0.70 - 1.26
Average	0.228	0.215	0.289	1.26	0.82 - 1.91	-0.114	0.153	0.456	0.89	0.66 - 1.21
High	0.100	0.214	0.640	1.11	0.73 - 1.68	-0.138	0.155	0.373	0.87	0.64 - 1.18
Very high	0.039	0.219	0.859	1.04	0.68-1.60	-0 133	0 169	0.430	0.88	0.63-1.22

Abbreviations: S.E., standard error; OR, odds ratio; CI, confidence interval; BMI, body mass index; SES, socioeconomic status. ^a Reference was participants who did not have metabolic syndrome.

the Iranian population and was used in the current study for further analysis.

One of the largest studies in the United States, analyzing data from the National Health and Nutrition Examination Survey (NHANES), showed that using the harmonized criteria for MetS, more than one-third of US adults met the criteria by 2012 (20). In a recent meta-analysis of 69 studies carried out in Iran, the overall prevalence of MetS in adults over 20 years of age was 30.4% (10). The prevalence of MetS in the same age group and criteria in the Iranian population was 33.1% (21), which is close to our results (34.5%). The prevalence of MetS has also been reported in other parts of the world, including 28.8% in Turkey (22), 25.9% in Denmark (23), 5.3% in Japan (24), 31.2% in Lebanon (25), 32% in Brazil (26), and 24.5% in China (27). The variability of these reports can be due to the different diagnostic criteria used for MetS, different age of the studied populations, nutrition, physical activity, and general lifestyle.

The high prevalence of MetS, given its potential consequences, calls for the identification of any etiological factors that may contribute to the development of MetS. Thus, we assessed the frequency of MetS components and the effect of sociodemographic factors such as age, gender, marital status, education, occupation, place of residence, SES, anthropometric indices, concentration of some serum elements, blood pressure, calorie intake, and physical activity on the presence of MetS in the study population. Furthermore, population-specific studies are very valuable, since there may be some unmeasurable factors involved that differ across populations.

Regarding the prevalence of individual components, central obesity, followed by decreased HDL, elevated FPG, hypertriglyceridemia, and raised BP were the most prevalent in our study population. The most important component of MetS is abdominal obesity, a metabolically active adipose tissue (28) associated with insulin resistance. Besides, it plays a critical role in MetS consequence (29). The results of a meta-analysis on the Iranian population (10), a study in south of Iran (21), as well as a Turkic ethnic study in Iran (30), demonstrated consistent findings in which abdominal obesity was the most common component. However, a study in southeastern Iran found hypertriglyceridemia as the dominant component (31). Ostovar et al. reported low HDL and high TG as more prevalent components among adult population (32). This might be explained by the difference in the age of the population, physical activity, and nutritional issues.

We found that participants with MetS were significantly older than those without MetS. Our study revealed that the odds of MetS increased quite steadily with age in women, having the same trend in men but only from 50 to 64 years of age, with a slight decrease after the age of 64. More than 80% of MetS subjects were over 45 years of age in our study. Also, a Northern Indian study results revealed that more than 80% of MetS population were over 40 years (33). Moreover, women with MetS were significantly older than men with MetS. Besides, the older subjects had a higher number of components, and dysglycemia and high BP were more prevalent among older patients. Similarly, in the study by Moore et al., advanced age significantly increased the odds of MetS (20). Also, in line with the findings of our study, in a 12-year cohort of Iranian adults, the prevalence of MetS increased up to the age of 75 (10). The increased prevalence of MetS among older adults could be justified by age-dependent hormonal alterations in insulin and counter-regulatory hormones as well as increased sedentary lifestyle in older adults, probably due to functional disabilities (34, 35).

Our study showed that the prevalence of MetS was higher in women (37.6%) compared to men (30.1%). This result is in agreement with the findings of a recent metaanalysis of Iranian studies (10), the study by Nikbakht et al. (21), and Jahangiry et al.'s research (30). Our findings demonstrated that the prevalence of MetS components in MetS subjects, as well as their number, were higher in women than men in all age categories. Women more frequently presented central obesity and dysglycemia, while in men, hypertriglyceridemia and dysglycemia were more frequent. This was different in younger subjects. Although abdominal obesity and reduced HDL were the most common elements in younger females, hypertriglyceridemia and elevated WC were the most common in younger men. High BP and dysglycemia were the most common components in the elderly population compared to younger adults in both genders. In addition, these components had significant growth between 35 and 70 years of age. An increasing trend in abdominal obesity was observed up to 60 years of age in women; however, the increasing trend of abdominal obesity was relatively steady in men across all age groups. Farmanfarma et al. and Nikbakht et al. reported similar findings (10, 21) with regard to the frequency of MetS components.

Gender has a fundamental effect on MetS risk factors and components such as dyslipidemia, dysglycemia, and central obesity (36). The gender effect is a consequence of the difference in the distribution of adipose tissue between men and women. It is demonstrated that IFG is more common in men, especially in older age groups; conversely, impaired glucose tolerance (IGT) is more frequent in women. On the other hand, the global prevalence of obesity is higher in women compared to men (37). Although the precise mechanisms of gender differences remain to be fully elucidated, the amount and distribution of adipose tissue, different patterns of insulin resistance, sex hormone alterations during menopause, and nutritional factors have been proposed as possible reasons (38). In addition, different genetic background, socio-demographic characteristics, physical activity status, and nutritional factors can influence the gender differences regarding the prevalence of MetS and its components.

In our study, logistic regression showed a significant association between education and MetS in women. This is in agreement with the findings of previous studies. Dutra et al. demonstrated that education can be a protective factor against MetS in women (26).

Also, we found that living in rural areas was associated with MetS in women, which is in agreement with the Asian population studies. They found that rural residents consume less vegetables and having a high-calorie diet (39, 40). Other studies reported that a vegetable-rich diet was associated with a lower risk of MetS and its components, including high BP and hyperglycemia (41, 42). However, we did not have the details of dietary components in our study. Contrarily, other studies demonstrated a higher frequency of MetS in urban-dwelling subjects compared to our study (43, 44).

One interesting issue is that in the current study, 71.8% of women had < 6 years of education (in comparison with 44.3% in men). It might be due to cultural issues affecting the degree of education by gender. Moreover, every one more year of education decreased the risk of MetS by nearly 5% in illiterate women. Nikbakht et al. also reported the same results (21).

Although the prevalence of MetS was higher in those with average and high SES, there was no significant association between SES and MetS in our study. This was contrary to the findings of Zuo et al., who reported that high income was positively associated with MetS risk (45). Moore et al. also found contradictory results; low SES was strongly associated with MetS in their study (20). Our study was conducted as the first large population-based study in Hormozgan province, a south coastal area of Iran, by valid and precise measurements and protocols. A large sample size is another privilege of the study. One limitation of our study was its cross-sectional design. Furthermore, over 90% of the participants had low physical activity at baseline, which could not be an effective indicator of physical activity for comparison between subjects with and without MetS. Besides, we did not have the complementary nutritional information at the time of analysis.

Given the high prevalence of MetS and its components (central obesity, high TG, and low HDL), especially in younger individuals, all considered as cardiovascular risk factors, it will be critical for research studies to focus on identifying etiological factors and for governments to work on prevention strategies for MetS. Populationspecific studies such as ours are essential for identifying groups of people at higher risk of MetS for which tailored disease management strategies may be needed. A good strategy to prevent MetS would be to identify individuals with a lower number of abnormal MetS components than what is required for the diagnosis of MetS, for instance, those with only one component of MetS, and then take measures to avoid an increase in abnormal components or the development of MetS.

Supplementary Material

Supplementary material(s) is available here [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Acknowledgments

BKNCD is a part of PERSIAN national cohort, and we would like to thank Professor Reza Malekzadeh, Deputy of Research and Technology at the Ministry of Health and Medical Education of Iran and Director of the PERSIAN cohort, and Dr. Hossein Poustchi, Executive Director of the PERSIAN cohort, for all their supports during design and running of BKNCD. We also appreciate the dedicated efforts of Professor Teamur Aghamolaei, Vice-chancellor for Research of Hormozgan University of Medical Sciences. The Iranian Ministry of Health and Medical Education has contributed to the funding used in the PERSIAN Cohort through grant number 700/534.

Footnotes

Authors' Contribution: Study concept and design: M. K., and G. Z.; Acquisition of data: M. S.; Analysis and interpretation of data: G. Z.; Drafting of the manuscript: M. K.; Critical revision of the manuscript: Z. G; Study supervision: A. N.

Conflict of Interests: The authors declare that they had no competing interests.

Data Reproducibility: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval: The study received ethics approval (ethics code: IR.HUMS.REC.1397.176) from the Ethics Committee of Hormozgan Univerof Medical Sciences and it complies with sitv statements of the Declaration of Helsinki. the https://ethics.research.ac.ir/EthicsProposalView.php?id = 23376.

Funding/Support: The Iranian Ministry of Health and Medical Education has contributed to funding used in the PERSIAN Cohort through grant number 700/534.

Informed Consent: Informed consent was obtained from all subjects and a parent and/or legal guardian for vulnerable population.

References

- Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 2009;**120**(16):1640–5. doi: 10.1161/CIRCULATION-AHA.109.192644. [PubMed: 19805654].
- Alberti KM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. *Lancet.* 2005;**366**(9491):1059–62. doi: 10.1016/s0140-6736(05)67402-8.
- Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97. doi: 10.1001/jama.285.19.2486. [PubMed: 11368702].
- Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*. 2005;**112**(17):2735–52. doi: 10.1161/CIRCULATIONAHA.105.169404. [PubMed: 16157765].
- Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the AT-PIII and the WHO definitions. *Diabetes Res Clin Pract.* 2007;77(2):251–7. doi:10.1016/j.diabres.2006.12.001. [PubMed: 17234299].
- James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20. doi: 10.1001/jama.2013.284427. [PubMed: 24352797].
- Kaur J. A comprehensive review on metabolic syndrome. *Cardiol Res Pract.* 2014;2014:943162. doi: 10.1155/2014/943162. [PubMed: 24711954]. [PubMed Central: PMC3966331].
- Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. *Diabetes Care*. 2005;28(7):1769–78. doi: 10.2337/diacare.28.7.1769. [PubMed: 15983333].
- Ghaem Maralani H, Tai BC, Wong TY, Tai ES, Li J, Wang JJ, et al. Metabolic syndrome and mortality in the elderly: a timedependent association. *Diabetes Res Clin Pract.* 2013;**99**(2):209–16. doi: 10.1016/j.diabres.2012.11.005. [PubMed: 23206672].
- Kalan Farmanfarma K, Kaykhaei MA, Adineh HA, Mohammadi M, Dabiri S, Ansari-Moghaddam A. Prevalence of metabolic syndrome in Iran: A meta-analysis of 69 studies. *Diabetes Metab Syndr.* 2019;**13**(1):792–9. doi: 10.1016/j.dsx.2018.11.055. [PubMed: 30641809].
- Nakao YM, Miyawaki T, Yasuno S, Nakao K, Tanaka S, Ida M, et al. Intra-abdominal fat area is a predictor for new onset of individual components of metabolic syndrome: MEtabolic syndRome and abdominal ObesiTy (MERLOT study). Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(8):454–61. doi: 10.2183/pjab.88.454. [PubMed: 23060233]. [PubMed Central: PMC3491080].

- Keane D, Kelly S, Healy NP, McArdle MA, Holohan K, Roche HM. Diet and metabolic syndrome: an overview. *Curr Vasc Pharmacol.* 2013;11(6):842-57. doi: 10.2174/15701611113116660173. [PubMed: 24168443].
- Teixeira TF, Alves RD, Moreira AP, Peluzio Mdo C. Main characteristics of metabolically obese normal weight and metabolically healthy obese phenotypes. *Nutr Rev.* 2015;73(3):175–90. doi: 10.1093/nutrit/nuu007. [PubMed: 26024540].
- Xi B, He D, Hu Y, Zhou D. Prevalence of metabolic syndrome and its influencing factors among the Chinese adults: the China Health and Nutrition Survey in 2009. *Prev Med*. 2013;57(6):867-71. doi: 10.1016/j.ypmed.2013.09.023. [PubMed: 24103567]. [PubMed Central: PMC4044099].
- Hajian-Tilaki K, Heidari B, Firouzjahi A, Bagherzadeh M, Hajian-Tilaki A, Halalkhor S. Prevalence of metabolic syndrome and the association with socio-demographic characteristics and physical activity in urban population of Iranian adults: a population-based study. *Diabetes Metab Syndr*. 2014;8(3):170–6. doi: 10.1016/j.dsx.2014.04.012. [PubMed: 25220921].
- Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar AA, Hekmatdoost A, et al. Prospective Epidemiological Research Studies in Iran (the PERSIAN Cohort Study): Rationale, Objectives, and Design. *Am J Epidemiol.* 2018;**187**(4):647–55. doi: 10.1093/aje/kwx314. [PubMed: 29145581]. [PubMed Central: PMC6279089].
- World Health Organization. Waist circumference and waist-hip ratio: Report of a WHO expert consultation, , 8-11 December 2008. Geneva, Switzerland: World Health Organization; 2011.
- Azizi F, Khalili D, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, et al. Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity. Iranian National Committee of Obesity; 2010.
- Azizi F, Hadaegh F, Khalili D, Esteghamati A, Hossein PF, Delavari A, et al. Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity. Iranian National Committee of Obesity; 2010.
- Moore JX, Chaudhary N, Akinyemiju T. Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. *Prev Chronic Dis.* 2017;**14**. E24. doi: 10.5888/pcd14.160287. [PubMed: 28301314]. [PubMed Central: PMC5364735].
- Nikbakht HA, Rezaianzadeh A, Seif M, Ghaem H. Factor Analysis of Metabolic Syndrome Components in a Population-Based Study in the South of Iran (PERSIAN Kharameh Cohort Study). *Iran J Public Health*. 2021;**50**(9):1863–71. doi: 10.18502/ijph.v50i9.7059. [PubMed: 34722382]. [PubMed Central: PMC8542825].
- Gundogan K, Bayram F, Capak M, Tanriverdi F, Karaman A, Ozturk A, et al. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia. *Metab Syndr Relat Disord*. 2009;7(5):427-34. doi: 10.1089/met.2008.0068. [PubMed: 19754305].
- Moller Pedersen SF, Jepsen JR. The metabolic syndrome among Danish seafarers. Int Marit Health. 2013;64(4):183–90. doi: 10.5603/imh.2013.0002. [PubMed: 24408138].
- 24. Urashima M, Wada T, Fukumoto T, Joki M, Maeda T, Hashimoto H, et al. Prevalence of metabolic syndrome in a 22,892 Japanese population and its associations with life style. *Japan Med Assoc J.* 2005;48(9):441.
- Ahmadpour F, Ahmadpour F, Rassouli ZB, Ardabili HM, Azimi Nezhad M. A Review on Underlying Differences in the Prevalence of Metabolic Syndrome in the Middle East, Europe and North America. J Mol Gen Med. 2014;2(s1). doi: 10.4172/1747-0862.S1-019.
- Dutra ES, de Carvalho KM, Miyazaki E, Hamann EM, Ito MK. Metabolic syndrome in central Brazil: prevalence and correlates in the adult population. *Diabetol Metab Syndr*. 2012;4(1):20. doi: 10.1186/1758-5996-4-20. [PubMed: 22583910]. [PubMed Central: PMC3457864].
- 27. Li R, Li W, Lun Z, Zhang H, Sun Z, Kanu JS, et al. Prevalence of metabolic syndrome in Mainland China: a meta-analysis of pub-

lished studies. *BMC Public Health*. 2016;**16**:296. doi: 10.1186/s12889-016-2870-y. [PubMed: 27039079]. [PubMed Central: PMC4818385].

- Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. *Nature*. 2006;444(7121):881-7. doi: 10.1038/nature05488. [PubMed: 17167477].
- Wang HH, Lee DK, Liu M, Portincasa P, Wang DQ. Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome. *Pediatr Gastroenterol Hepatol Nutr.* 2020;23(3):189–230. doi: 10.5223/pghn.2020.23.3.189. [PubMed: 32483543]. [PubMed Central: PMC7231748].
- Jahangiry L, Khosravi-Far L, Sarbakhsh P, Kousha A, EntezarMahdi R, Ponnet K. Prevalence of metabolic syndrome and its determinants among Iranian adults: evidence of IraPEN survey on a bi-ethnic population. *Sci Rep.* 2019;9(1):1–7. doi: 10.1038/s41598-019-44486-8. [PubMed: 31138853]. [PubMed Central: PMC6538652].
- Kaykhaei MA, Hashemi M, Narouie B, Shikhzadeh A, Jahantigh M, Shirzaei E, et al. Prevalence of metabolic syndrome in adult population from zahedan, southeast iran. *Iran J Public Health*. 2012;**41**(2):70.
- Ostovar R, Kiani F, Sayehmiri F, Yasemi M, Mohsenzadeh Y, Mohsenzadeh Y. Prevalence of metabolic syndrome in Iran: A meta-analysis. *Electron Physician*. 2017;9(10):5402-18. doi: 10.19082/5402. [PubMed: 29238477]. [PubMed Central: PMC5718841].
- Khan Y, Lalchandani A, Gupta AC, Khadanga S, Kumar S. Prevalence of metabolic syndrome crossing 40% in Northern India: Time to act fast before it runs out of proportions. *J Family Med Prim Care*. 2018;7(1):118–23. doi: 10.4103/jfmpc.jfmpc_10_17. [PubMed: 29915744]. [PubMed Central: PMC5958552].
- Strath S, Swartz A, Parker S, Miller N, Cieslik L. Walking and Metabolic Syndrome in Older Adults. J Phys Act Health. 2007;4(4):398–411. doi: 10.1123/jpah.4.4.398.
- Mankowski RT, Aubertin-Leheudre M, Beavers DP, Botoseneanu A, Buford TW, Church T, et al. Sedentary time is associated with the metabolic syndrome in older adults with mobility limitations-The LIFE Study. *Exp Gerontol.* 2015;**70**:32–6. doi: 10.1016/j.exger.2015.06.018. [PubMed: 26130060]. [PubMed Central: PMC4600654].
- Pradhan AD. Sex differences in the metabolic syndrome: implications for cardiovascular health in women. *Clin Chem.* 2014;60(1):44–52. doi:

10.1373/clinchem.2013.202549. [PubMed: 24255079].

- Faulkner JL, Belin de Chantemele EJ. Sex hormones, aging and cardiometabolic syndrome. *Biol Sex Differ*. 2019;**10**(1):30. doi: 10.1186/s13293-019-0246-6. [PubMed: 31262349]. [PubMed Central: PMC6604485].
- Sarrafzadegan N, Gharipour M, Sadeghi M, Khosravi AR, Tavassoli AA. Metabolic syndrome in Iranian elderly. ARYA Atheroscler. 2012;7(4):157.
- Lee S, Shin Y, Kim Y. Risk of Metabolic Syndrome among Middle-Aged Koreans from Rural and Urban Areas. *Nutrients*. 2018;10(7):859. doi: 10.3390/nu10070859. [PubMed: 29970821]. [PubMed Central: PMC6073562].
- Guo H, Gao X, Ma R, Liu J, Ding Y, Zhang M, et al. Prevalence of Metabolic Syndrome and its Associated Factors among Multiethnic Adults in Rural Areas in Xinjiang, China. *Sci Rep.* 2017;7(1):1–9. doi: 10.1038/s41598-017-17870-5. [PubMed: 29247195]. [PubMed Central: PMC5732195].
- Hong SA, Kim MK. Relationship between fruit and vegetable intake and the risk of metabolic syndrome and its disorders in Korean women according to menopausal status. *Asia Pac J Clin Nutr.* 2017;**26**(3):514-23.
- 42. Martini FAN, Borges MB, Guedes DP. [Eating habit and metabolic syndrome in a sample of Brazilian adults. Archivos latinoamericanos]. *Arch Latinoam Nutr.* 2014;**64**(3):161–73. Portuguese.
- Weng X, Liu Y, Ma J, Wang W, Yang G, Caballero B. An urbanrural comparison of the prevalence of the metabolic syndrome in Eastern China. *Public Health Nutr.* 2007;10(2):131–6. doi: 10.1017/S1368980007226023. [PubMed: 17261221].
- Moreno-Ulloa J, Moreno-Ulloa A, Martinez-Tapia M, Duque-Rodriguez J. Comparison of the prevalence of metabolic syndrome and risk factors in urban and rural Mexican Tarahumara-foot runners. *Diabetes Res Clin Pract*. 2018;**143**:79–87. doi: 10.1016/j.diabres.2018.06.015. [PubMed: 29936251].
- Zuo H, Shi Z, Hu X, Wu M, Guo Z, Hussain A. Prevalence of metabolic syndrome and factors associated with its components in Chinese adults. *Metabolism*. 2009;58(8):1102–8. doi: 10.1016/j.metabol.2009.04.008. [PubMed: 19481771].